Assertio Holdings Inc(NASDAQ:ASRT) 
Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis...
Website: https://www.assertiotx.com/
Founded: 1995
Full Time Employees: 125
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenues: | ||||||||||||||||||||||||
product sales | 8,898,000 | 12,823,000 | 49,459,000 | 28,822,000 | 25,994,000 | 29,587,000 | 28,705,000 | 30,695,000 | 31,862,000 | 32,462,000 | 35,137,000 | 40,083,000 | 41,769,000 | 49,863,000 | 34,279,000 | 35,430,000 | 35,546,000 | 32,149,000 | 25,997,000 | 24,831,000 | 26,405,000 | 29,815,000 | 34,266,000 | 20,165,000 |
royalty revenue | 435,000 | 719,000 | 400,000 | 494,000 | ||||||||||||||||||||
other revenue | 600,000 | 185,000 | -540,000 | -750,000 | -9,000 | -941,000 | ||||||||||||||||||
total revenues | 9,933,000 | 13,542,000 | 49,459,000 | 29,222,000 | 26,488,000 | 32,183,000 | 29,204,000 | 31,126,000 | 32,448,000 | 32,985,000 | 35,627,000 | 40,991,000 | 42,466,000 | 50,350,000 | 34,212,000 | 35,131,000 | 36,538,000 | 33,328,000 | 25,472,000 | 25,373,000 | 26,839,000 | 30,176,000 | 34,565,000 | 20,617,000 |
yoy | -62.50% | -57.92% | 69.36% | -6.12% | -18.37% | -2.43% | -18.03% | -24.07% | -23.59% | -34.49% | 4.14% | 16.68% | 16.22% | 51.07% | 34.31% | 38.46% | 36.14% | 10.45% | -26.31% | 23.07% | ||||
qoq | -26.65% | -72.62% | 69.25% | 10.32% | -17.70% | 10.20% | -6.17% | -4.07% | -1.63% | -7.42% | -13.09% | -3.47% | -15.66% | 47.17% | -2.62% | -3.85% | 9.63% | 30.84% | 0.39% | -5.46% | -11.06% | -12.70% | 67.65% | |
costs and expenses: | ||||||||||||||||||||||||
cost of sales | 2,711,000 | 3,266,000 | 13,654,000 | 10,677,000 | 7,786,000 | 11,611,000 | 7,550,000 | 8,889,000 | 11,177,000 | 9,721,000 | 7,060,000 | 4,772,000 | 5,467,000 | 6,014,000 | 4,009,000 | 4,528,000 | 4,195,000 | 4,896,000 | 3,050,000 | 3,921,000 | 3,966,000 | 6,773,000 | 6,462,000 | 5,238,000 |
gross profit | 7,222,000 | 10,276,000 | 35,805,000 | 18,545,000 | 18,702,000 | 20,572,000 | 21,654,000 | 22,237,000 | 21,271,000 | 23,264,000 | 28,567,000 | 36,219,000 | 36,999,000 | 44,336,000 | 30,203,000 | 30,603,000 | 32,343,000 | 28,432,000 | 22,422,000 | 21,452,000 | 22,873,000 | 23,403,000 | 28,103,000 | 15,379,000 |
yoy | -61.38% | -50.05% | 65.35% | -16.60% | -12.08% | -11.57% | -24.20% | -38.60% | -42.51% | -47.53% | -5.42% | 18.35% | 14.40% | 55.94% | 34.70% | 42.66% | 41.40% | 21.49% | -20.21% | 39.49% | ||||
qoq | -29.72% | -71.30% | 93.07% | -0.84% | -9.09% | -5.00% | -2.62% | 4.54% | -8.57% | -18.56% | -21.13% | -2.11% | -16.55% | 46.79% | -1.31% | -5.38% | 13.76% | 26.80% | 4.52% | -6.21% | -2.26% | -16.72% | 82.74% | |
gross margin % | 72.71% | 75.88% | 72.39% | 63.46% | 70.61% | 63.92% | 74.15% | 71.44% | 65.55% | 70.53% | 80.18% | 88.36% | 87.13% | 88.06% | 88.28% | 87.11% | 88.52% | 85.31% | 88.03% | 84.55% | 85.22% | 77.56% | 81.30% | 74.59% |
research and development expenses | 454,000 | 486,000 | 379,000 | 387,000 | 438,000 | 1,286,000 | 1,005,000 | 798,000 | 733,000 | 1,024,000 | 1,316,000 | 503,000 | 230,000 | 1,316,000 | 1,626,000 | |||||||||
selling, general and administrative expenses | 19,434,000 | 13,135,000 | 16,930,000 | 16,960,000 | 21,975,000 | 21,416,000 | 16,726,000 | 18,385,000 | 18,524,000 | 23,958,000 | 21,005,000 | 16,771,000 | 16,904,000 | 13,702,000 | 11,900,000 | 10,543,000 | 10,638,000 | 13,276,000 | 9,313,000 | 26,235,000 | 7,730,000 | 23,133,000 | 25,746,000 | 28,131,000 |
amortization of intangible assets | 5,804,000 | 5,804,000 | 5,594,000 | 9,233,000 | 9,233,000 | 6,671,000 | 6,671,000 | 6,671,000 | 5,631,000 | 4,775,000 | 10,184,000 | 6,284,000 | 6,284,000 | 8,170,000 | 7,969,000 | 7,969,000 | 8,501,000 | 7,175,000 | 7,175,000 | 7,218,000 | 6,547,000 | 6,546,000 | 5,587,000 | 4,855,000 |
restructuring charges | 2,600,000 | 289,000 | 720,000 | 2,442,000 | 3,034,000 | 1,089,000 | 11,019,000 | 268,000 | 6,519,000 | |||||||||||||||
total costs and expenses | 28,403,000 | 25,291,000 | 37,981,000 | 37,257,000 | 39,721,000 | 45,657,000 | 32,252,000 | 34,743,000 | 36,785,000 | 65,314,000 | 263,898,000 | 28,571,000 | 37,822,000 | 39,728,000 | 27,778,000 | 24,340,000 | 24,979,000 | 25,347,000 | 19,538,000 | 37,374,000 | 19,332,000 | 65,133,000 | 39,379,000 | 46,369,000 |
income from operations | -18,470,000 | -11,749,000 | 11,478,000 | -8,035,000 | -13,233,000 | -13,474,000 | -3,048,000 | -3,617,000 | -4,337,000 | -32,329,000 | -228,271,000 | 12,420,000 | 4,644,000 | 10,622,000 | 6,434,000 | 10,791,000 | 11,559,000 | 7,981,000 | 5,934,000 | -12,001,000 | 7,507,000 | -34,957,000 | -4,814,000 | -25,752,000 |
yoy | 39.58% | -12.80% | -476.57% | 122.15% | 205.12% | -58.32% | -98.66% | -129.12% | -193.39% | -404.36% | -3647.89% | 15.10% | -59.82% | 33.09% | 8.43% | -189.92% | 53.98% | -122.83% | -223.27% | -53.40% | ||||
qoq | 57.20% | -202.36% | -242.85% | -39.28% | -1.79% | 342.06% | -15.73% | -16.60% | -86.58% | -85.84% | -1937.93% | 167.44% | -56.28% | 65.09% | -40.38% | -6.64% | 44.83% | 34.50% | -149.45% | -259.86% | -121.47% | 626.15% | -81.31% | |
operating margin % | -185.95% | -86.76% | 23.21% | -27.50% | -49.96% | -41.87% | -10.44% | -11.62% | -13.37% | -98.01% | -640.72% | 30.30% | 10.94% | 21.10% | 18.81% | 30.72% | 31.64% | 23.95% | 23.30% | -47.30% | 27.97% | -115.84% | -13.93% | -124.91% |
other income: | ||||||||||||||||||||||||
interest expense | -775,000 | -772,000 | -770,000 | -768,000 | -765,000 | -763,000 | -761,000 | -758,000 | -757,000 | -755,000 | -752,000 | -751,000 | -1,122,000 | -1,313,000 | -2,052,000 | -2,269,000 | -2,327,000 | -2,437,000 | -2,495,000 | -2,605,000 | -2,684,000 | -2,598,000 | -3,050,000 | -1,604,000 |
interest income | 469,000 | 606,000 | 664,000 | 675,000 | 720,000 | 780,000 | 887,000 | 842,000 | ||||||||||||||||
other loss | -35,000 | -499,000 | ||||||||||||||||||||||
total other expense | -341,000 | -63,000 | -41,000 | 424,000 | -614,000 | -90,000 | -10,238,000 | -1,548,750 | -2,050,000 | -2,364,000 | -1,782,000 | |||||||||||||
net loss before income taxes | -18,811,000 | -16,296,000 | -13,296,000 | -10,749,000 | -2,877,000 | -4,378,000 | -14,469,000 | -43,971,000 | ||||||||||||||||
income tax expense | -45,000 | -56,000 | -245,000 | 273,000 | -44,000 | -149,000 | -13,102,250 | -50,659,000 | -3,860,000 | -379,000 | -210,000 | -713,000 | -548,000 | |||||||||||
net loss and comprehensive loss | -18,856,000 | -16,352,000 | -13,541,000 | -10,476,000 | -2,921,000 | -4,510,000 | ||||||||||||||||||
basic and diluted net loss per share* | -2.93 | |||||||||||||||||||||||
shares used in computing basic and diluted net loss per share* | 6,434 | |||||||||||||||||||||||
change in fair value of contingent consideration | -276,000 | -544,000 | 300,000 | -17,414,000 | -17,532,000 | 241,000 | -465,250 | -1,861,000 | ||||||||||||||||
impairment of intangible assets | 1,700,000 | |||||||||||||||||||||||
loss on assertio therapeutics divestiture | -8,174,000 | |||||||||||||||||||||||
other gain | 169,000 | 26,000 | 6,000 | -18,000 | 2,708,000 | 45,000 | 8,000 | 716,000 | 1,179,000 | 138,000 | 661,000 | 802,000 | -731,000 | 2,000 | -95,000 | 545,000 | -504,000 | 344,000 | 137,000 | 269,000 | 346,000 | 253,000 | ||
total other income | 3,000 | -80,000 | -8,261,000 | 2,725,000 | 171,000 | 92,000 | -2,941,000 | -2,151,000 | -2,468,000 | -2,415,000 | -391,000 | -4,658,000 | -18,219,000 | |||||||||||
net income before income taxes | -4,548,500 | 11,398,000 | -3,525,000 | -31,905,000 | -228,885,000 | 12,330,000 | -5,594,000 | 8,578,000 | 4,384,000 | 8,427,000 | 9,777,000 | 5,040,000 | 3,783,000 | 5,092,000 | -35,348,000 | -9,472,000 | ||||||||
income tax benefit | -63,500 | 47,000 | -132,000 | 2,110,000 | -593,000 | -434,000 | -46,000 | 300,000 | 10,995,000 | -1,050,000 | 9,472,000 | |||||||||||||
net income and comprehensive loss | -4,612,000 | 11,445,000 | -57,384,000 | -279,544,000 | 8,470,000 | -3,484,000 | 88,553,000 | 4,174,000 | 7,834,000 | 9,064,000 | 4,606,000 | 3,737,000 | -14,169,000 | 4,544,000 | -24,353,000 | -10,522,000 | -34,499,000 | |||||||
yoy | -164.80% | -6797.27% | 8.12% | -138.44% | 1822.56% | 11.69% | -155.29% | 99.47% | -118.91% | -135.52% | -58.93% | |||||||||||||
qoq | -140.30% | -79.47% | -3400.40% | -343.11% | -103.93% | 2021.54% | -46.72% | -13.57% | 96.79% | 23.25% | -126.37% | -411.82% | -118.66% | 131.45% | -69.50% | |||||||||
net income margin % | 0% | -34.06% | 23.14% | 0% | 0% | 0% | 0% | 0% | 0% | -173.97% | -784.64% | 20.66% | -8.20% | 175.87% | 12.20% | 22.30% | 24.81% | 13.82% | 14.67% | -55.84% | 16.93% | -80.70% | -30.44% | -167.33% |
basic net income per share | -0.048 | 0.12 | -0.04 | -0.32 | -3.42 | 0.15 | -0.07 | 1.88 | 0.09 | 0.17 | 0.2 | 0.11 | 0.08 | -0.32 | 0.03 | -0.35 | ||||||||
diluted net income per share | -0.048 | 0.11 | -0.04 | -0.32 | -3.42 | 0.13 | -0.07 | 1.61 | 0.08 | 0.16 | 0.2 | 0.11 | 0.08 | -0.32 | 0.03 | -0.35 | ||||||||
shares used in computing basic net income per share | 23,991.5 | 96,245 | 95,240 | 7,965 | 81,713 | 56,142 | 51,005 | 438 | 48,180 | 46,274 | 45,204 | 619 | 44,969 | 44,706 | 151,296 | 98,558 | ||||||||
shares used in computing diluted net income per share | 23,991.5 | 106,514 | 95,240 | 7,965 | 81,713 | 70,144 | 51,005 | 4,199 | 57,386 | 47,579 | 46,127 | 619 | 45,055 | 44,706 | 153,918 | 98,558 | ||||||||
basic and diluted net loss per share | -0.17 | -0.14 | -0.05 | |||||||||||||||||||||
shares used in computing basic and diluted net loss per share | 95,970 | 95,677 | 94,980 | |||||||||||||||||||||
royalties and milestones | 496,000 | 499,000 | 431,000 | 586,000 | 523,000 | 490,000 | 723,000 | 697,000 | 487,000 | 473,000 | 451,000 | 992,000 | 1,188,000 | 416,000 | 542,000 | 434,000 | 361,000 | 299,000 | 452,000 | |||||
loss on impairment of intangible assets | 40,808,000 | 238,831,000 | ||||||||||||||||||||||
debt-related expenses | -2,479,500 | -9,918,000 | ||||||||||||||||||||||
basic net loss per share | -0.03 | -0.03 | ||||||||||||||||||||||
diluted net loss per share | -0.03 | -0.03 | ||||||||||||||||||||||
shares used in computing basic net loss per share | 23,797.75 | 95,352 | ||||||||||||||||||||||
shares used in computing diluted net loss per share | 23,797.75 | 95,352 | ||||||||||||||||||||||
comprehensive income | -3,674,000 | |||||||||||||||||||||||
fair value of contingent consideration | 9,167,000 | 11,842,000 | 3,900,000 | 1,300,000 | 1,645,000 | |||||||||||||||||||
commercialization agreement | ||||||||||||||||||||||||
other income : | ||||||||||||||||||||||||
gain on sale of gralise | -850,000 | |||||||||||||||||||||||
loss on extinguishment of convertible notes | -16,272,000 | |||||||||||||||||||||||
loss on sale of nucynta | ||||||||||||||||||||||||
loss on debt extinguishment | ||||||||||||||||||||||||
gain on sale of nucynta | 1,006,000 | |||||||||||||||||||||||
gain on extinguishment of convertible notes | -11,970,000 | |||||||||||||||||||||||
loss on prepayment of senior notes | -2,058,250 | |||||||||||||||||||||||
basic and diluted net income per share | -0.01 | -0.09 | ||||||||||||||||||||||
shares used in computing basic and diluted net income per share | 24,958 | 119,564 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||
current assets: | ||||||||||||||||||||||||
cash and cash equivalents | 33,713,000 | 10,229,000 | 38,500,000 | 47,086,000 | 35,004,000 | 50,588,000 | 37,981,000 | 44,735,000 | 80,743,000 | 73,441,000 | 76,888,000 | 70,175,000 | 68,603,000 | 64,941,000 | 64,826,000 | 52,264,000 | 61,389,000 | 36,810,000 | 58,726,000 | 54,428,000 | 61,033,000 | 20,786,000 | 34,737,000 | 59,403,000 |
short-term investments | 37,856,000 | 53,176,000 | 54,927,000 | 51,097,000 | 52,321,000 | 49,466,000 | 50,598,000 | 43,644,000 | ||||||||||||||||
accounts receivable | 61,527,000 | 120,110,000 | 141,307,000 | 61,090,000 | 66,292,000 | 54,120,000 | 44,944,000 | 39,913,000 | 42,610,000 | 47,663,000 | 62,467,000 | 41,608,000 | 46,466,000 | 45,357,000 | 44,680,000 | 48,537,000 | 48,923,000 | 44,361,000 | 36,145,000 | 45,468,000 | 39,241,000 | 44,350,000 | 39,223,000 | 34,753,000 |
inventories | 23,010,000 | 24,120,000 | 24,763,000 | 32,880,000 | 39,403,000 | 38,308,000 | 39,788,000 | 39,080,000 | 38,602,000 | 37,686,000 | 42,710,000 | 18,817,000 | 16,226,000 | 13,696,000 | 14,268,000 | 12,259,000 | 9,480,000 | 7,489,000 | 5,481,000 | 6,617,000 | 8,930,000 | 11,712,000 | 13,469,000 | 25,398,000 |
prepaid and other current assets | 10,749,000 | 9,011,000 | 4,076,000 | 18,056,000 | 20,530,000 | 10,067,000 | 7,845,000 | 10,480,000 | 10,519,000 | 12,272,000 | 2,895,000 | 2,949,000 | 6,554,000 | 8,268,000 | 2,720,000 | 3,632,000 | 5,323,000 | 14,838,000 | 12,193,000 | 12,835,000 | 14,865,000 | 17,406,000 | 17,063,000 | 15,909,000 |
total current assets | 166,855,000 | 216,646,000 | 263,573,000 | 210,209,000 | 213,550,000 | 202,549,000 | 181,156,000 | 177,852,000 | 172,474,000 | 171,062,000 | 184,960,000 | 133,549,000 | 137,849,000 | 132,262,000 | 126,494,000 | 116,692,000 | 125,115,000 | 103,498,000 | 112,545,000 | 119,348,000 | 124,069,000 | 94,254,000 | 104,492,000 | 135,463,000 |
property and equipment | 408,000 | 444,000 | 479,000 | 515,000 | 550,000 | 586,000 | 624,000 | 664,000 | 704,000 | 770,000 | 804,000 | 877,000 | 544,000 | 744,000 | 935,000 | 1,133,000 | 1,329,000 | 1,527,000 | 1,678,000 | 1,915,000 | 2,172,000 | 2,437,000 | 3,773,000 | 7,349,000 |
intangible assets | 43,104,000 | 48,908,000 | 54,711,000 | 62,006,000 | 71,238,000 | 80,471,000 | 92,359,000 | 99,030,000 | 105,701,000 | 111,332,000 | 170,413,000 | 185,428,000 | 191,712,000 | 197,996,000 | 191,617,000 | 199,585,000 | 207,554,000 | 216,054,000 | 179,143,000 | 186,318,000 | 193,536,000 | 200,082,000 | 206,628,000 | 179,716,000 |
other long-term assets | 932,000 | 972,000 | 1,012,000 | 1,050,000 | 1,088,000 | 1,126,000 | 1,860,000 | 1,897,000 | 3,086,000 | 3,255,000 | 3,995,000 | 3,738,000 | 2,600,000 | 2,709,000 | 4,298,000 | 4,566,000 | 5,137,000 | 5,468,000 | 5,939,000 | 4,435,000 | 5,647,000 | 4,922,000 | 8,896,000 | 7,470,000 |
total assets | 211,299,000 | 266,970,000 | 319,775,000 | 273,780,000 | 286,426,000 | 284,732,000 | 275,999,000 | 279,443,000 | 281,965,000 | 286,419,000 | 380,028,000 | 405,179,000 | 414,274,000 | 413,913,000 | 323,344,000 | 321,976,000 | 339,135,000 | 326,547,000 | 299,305,000 | 312,016,000 | 325,424,000 | 303,274,000 | 332,797,000 | 345,724,000 |
liabilities and shareholders’ equity | ||||||||||||||||||||||||
current liabilities: | ||||||||||||||||||||||||
accounts payable | 5,913,000 | 9,014,000 | 14,664,000 | 10,854,000 | 8,896,000 | 14,736,000 | 13,153,000 | 15,271,000 | 15,650,000 | 13,439,000 | 19,004,000 | 11,182,000 | 6,173,000 | 5,991,000 | 8,374,000 | 9,415,000 | 8,523,000 | 6,685,000 | 7,666,000 | 16,483,000 | 10,609,000 | 14,808,000 | 22,981,000 | 28,535,000 |
accrued rebates, returns and discounts | 62,344,000 | 99,366,000 | 130,536,000 | 85,887,000 | 82,130,000 | 76,304,000 | 60,482,000 | 58,424,000 | 57,870,000 | 58,137,000 | 59,424,000 | 42,857,000 | 52,313,000 | 49,426,000 | 48,608,000 | 52,331,000 | 55,588,000 | 52,662,000 | 43,830,000 | 45,108,000 | 50,136,000 | 63,114,000 | 48,932,000 | 52,440,000 |
accrued liabilities | 18,485,000 | 14,282,000 | 16,263,000 | 31,055,000 | 33,037,000 | 18,847,000 | 12,964,000 | 15,124,000 | 15,401,000 | 18,213,000 | 22,065,000 | 10,283,000 | 10,799,000 | 12,181,000 | 10,992,000 | 13,232,000 | 15,386,000 | 14,699,000 | 13,782,000 | 22,867,000 | 19,567,000 | 31,571,000 | 33,062,000 | 31,564,000 |
other current liabilities | 4,831,000 | 4,851,000 | 4,870,000 | 4,007,000 | 4,043,000 | 4,075,000 | 505,000 | 665,000 | 823,000 | 954,000 | 996,000 | 256,000 | 332,000 | 948,000 | 11,247,000 | 16,010,000 | 32,159,000 | 34,299,000 | 11,552,000 | 11,641,000 | 2,637,000 | 2,682,000 | 3,085,000 | 3,005,000 |
total current liabilities | 91,573,000 | 127,513,000 | 166,783,000 | 132,529,000 | 128,832,000 | 114,688,000 | 90,104,000 | 92,184,000 | 92,444,000 | 93,443,000 | 114,289,000 | 79,478,000 | 94,545,000 | 95,316,000 | 92,296,000 | 116,150,000 | 138,527,000 | 135,019,000 | 100,480,000 | 116,914,000 | 109,090,000 | 132,686,000 | 131,374,000 | 134,372,000 |
long-term debt | 39,249,000 | 39,124,000 | 39,166,000 | 39,046,000 | 38,929,000 | 38,813,000 | 38,840,000 | 38,729,000 | 38,621,000 | 38,514,000 | 38,866,000 | 38,251,000 | 38,151,000 | 66,403,000 | 65,982,000 | 49,500,000 | 61,250,000 | 61,319,000 | 66,410,000 | 66,751,000 | 71,834,000 | 72,160,000 | 77,235,000 | 91,834,000 |
other long-term liabilities | 4,845,000 | 6,381,000 | 8,023,000 | 8,907,000 | 10,135,000 | 10,150,000 | 16,537,000 | 16,377,000 | 16,406,000 | 16,459,000 | 17,900,000 | 5,579,000 | 4,314,000 | 4,269,000 | 4,392,000 | 4,698,000 | 4,637,000 | 4,636,000 | 4,796,000 | 5,277,000 | 10,638,000 | 11,138,000 | 13,050,000 | 13,681,000 |
total liabilities | 135,667,000 | 173,018,000 | 213,972,000 | 180,482,000 | 177,896,000 | 163,651,000 | 145,481,000 | 147,290,000 | 147,471,000 | 148,416,000 | 187,155,000 | 150,908,000 | 163,610,000 | 188,188,000 | 188,429,000 | 193,607,000 | 227,273,000 | 224,133,000 | 202,445,000 | 219,751,000 | 220,121,000 | 247,760,000 | 256,847,000 | 260,746,000 |
commitments and contingencies | ||||||||||||||||||||||||
shareholders’ equity: | ||||||||||||||||||||||||
common stock, 0.0001 par value... | 1,000 | 1,000 | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | 18,000 | 13,000 | ||
additional paid-in capital | 797,986,000 | 797,366,000 | 796,306,000 | 795,186,000 | 794,196,000 | 793,157,000 | 791,871,000 | 790,538,000 | 789,537,000 | 787,023,000 | 568,881,000 | 573,744,000 | 545,321,000 | 543,064,000 | 540,692,000 | 532,020,000 | 531,636,000 | 530,689,000 | 529,831,000 | 528,686,000 | 483,446,000 | 479,530,000 | 478,037,000 | |
accumulated deficit | -722,355,000 | -703,499,000 | -691,572,000 | -703,017,000 | -686,665,000 | -673,124,000 | -662,648,000 | -659,727,000 | -656,053,000 | -651,543,000 | -594,159,000 | -314,615,000 | -323,085,000 | -319,601,000 | -408,154,000 | -412,328,000 | -420,162,000 | -429,226,000 | -433,833,000 | -437,570,000 | -423,401,000 | -427,945,000 | -403,592,000 | -393,070,000 |
total shareholders’ equity | 75,632,000 | 93,952,000 | 105,803,000 | 93,298,000 | 108,530,000 | 121,081,000 | 130,518,000 | 132,153,000 | 134,494,000 | 138,003,000 | 192,873,000 | 254,271,000 | 250,664,000 | 225,725,000 | 134,915,000 | 128,369,000 | 111,862,000 | 102,414,000 | 96,860,000 | 92,265,000 | 105,303,000 | 55,514,000 | 75,950,000 | 84,978,000 |
total liabilities and shareholders’ equity | 211,299,000 | 319,775,000 | ||||||||||||||||||||||
contingent consideration, current portion | 450,000 | 726,000 | 726,000 | 726,000 | 3,000,000 | 2,700,000 | 2,700,000 | 2,700,000 | 12,800,000 | 14,900,000 | 24,458,000 | 26,300,000 | 10,900,000 | 13,500,000 | 14,600,000 | 14,500,000 | 7,200,000 | 6,850,000 | 9,400,000 | 6,776,000 | 6,475,000 | 8,700,000 | ||
additional paid-in capital* | 797,450,000 | |||||||||||||||||||||||
total liabilities and shareholders' equity | 266,970,000 | 273,780,000 | 286,426,000 | 284,732,000 | 275,999,000 | 279,443,000 | 281,965,000 | 286,419,000 | 380,028,000 | 405,179,000 | 414,274,000 | 413,913,000 | 323,344,000 | 321,976,000 | 339,135,000 | 326,547,000 | 299,305,000 | 312,016,000 | 325,424,000 | 303,274,000 | 332,797,000 | 345,724,000 | ||
deferred tax asset | 81,587,000 | 81,569,000 | 80,202,000 | |||||||||||||||||||||
long-term debt, current portion | 470,000 | 470,000 | 2,175,000 | 11,662,000 | 12,271,000 | 12,174,000 | ||||||||||||||||||
contingent consideration | 16,100,000 | 27,600,000 | 26,600,000 | 22,200,000 | 25,759,000 | 23,259,000 | 22,859,000 | 23,159,000 | 30,759,000 | 30,809,000 | 28,559,000 | 31,776,000 | 35,188,000 | 20,859,000 | ||||||||||
goodwill | 19,856,000 | 9,008,000 | 14,147,000 | |||||||||||||||||||||
current portion of long-term debt | 12,257,000 | 12,222,000 | 12,338,000 | 11,942,000 | 11,010,000 | 7,374,000 | ||||||||||||||||||
interest payable | 4,193,000 | 1,743,000 | 4,403,000 | 1,793,000 | 5,829,000 | 2,754,000 | ||||||||||||||||||
investments | 1,579,000 | 1,579,000 | ||||||||||||||||||||||
common stock | 12,000 | 11,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
operating activities | |||||||||||||||||||||||
net loss | -18,856,000 | -11,927,000 | 11,445,000 | -16,352,000 | -13,541,000 | -10,476,000 | -4,510,000 | ||||||||||||||||
adjustments to reconcile net loss to net cash from operating activities: | |||||||||||||||||||||||
depreciation and amortization | 5,840,000 | 5,839,000 | 5,630,000 | 9,267,000 | 9,269,000 | 6,711,000 | 6,711,000 | 6,711,000 | 5,696,000 | 4,908,000 | 10,357,000 | 6,480,000 | 6,484,000 | 8,363,000 | 8,170,000 | 8,164,000 | 8,699,000 | 7,379,000 | 7,412,000 | 7,474,000 | 6,812,000 | 6,963,000 | 6,149,000 |
amortization of debt issuance costs | 125,000 | 122,000 | 120,000 | 118,000 | 115,000 | ||||||||||||||||||
accretion of interest income from short-term investments | 180,000 | 49,000 | 8,000 | -18,000 | 54,000 | -4,000 | -200,000 | ||||||||||||||||
recurring fair value measurements of assets and liabilities | 30,000 | -167,000 | -302,000 | 9,000 | 25,000 | -666,000 | 254,000 | -17,870,000 | -17,020,000 | 241,000 | 9,167,000 | ||||||||||||
provisions for inventory | 198,000 | 1,313,000 | 522,000 | 2,137,000 | 538,000 | ||||||||||||||||||
stock-based compensation | 725,000 | 97,000 | 1,067,000 | 1,189,000 | 1,101,000 | 1,098,000 | 1,296,000 | 1,408,000 | 1,207,000 | 2,642,000 | 1,865,000 | 2,205,000 | 2,446,000 | 2,388,000 | 2,400,000 | 1,734,000 | 982,000 | 949,000 | 867,000 | 957,000 | 772,000 | 3,886,000 | 1,511,000 |
changes in assets and liabilities: | |||||||||||||||||||||||
accounts receivable | 58,583,000 | 21,197,000 | -80,217,000 | 5,202,000 | -12,172,000 | -9,176,000 | -5,031,000 | 2,696,000 | 5,054,000 | 14,804,000 | 30,116,000 | 4,858,000 | -1,109,000 | -677,000 | 3,857,000 | 385,000 | -4,561,000 | -8,216,000 | 9,323,000 | -6,227,000 | 5,109,000 | -5,144,000 | -4,470,000 |
inventories | 912,000 | -670,000 | 7,595,000 | 4,386,000 | -1,633,000 | -2,499,000 | -1,813,000 | -2,927,000 | -2,344,000 | 3,925,000 | -2,387,000 | -2,909,000 | -3,602,000 | 1,014,000 | -2,578,000 | -3,007,000 | -2,022,000 | -2,049,000 | 1,362,000 | 2,324,000 | 2,631,000 | 501,000 | -1,304,000 |
prepaid and other assets | -1,698,000 | -4,896,000 | 14,017,000 | 2,513,000 | -10,425,000 | -1,488,000 | 2,672,000 | 1,229,000 | 1,921,000 | -7,938,000 | 2,480,000 | 2,465,000 | 1,824,000 | -5,269,000 | 1,180,000 | 2,263,000 | 9,845,000 | -2,698,000 | -863,000 | 3,245,000 | 3,395,000 | 1,981,000 | 4,006,000 |
accounts payable and other accrued liabilities | 196,000 | -9,955,000 | -10,351,000 | -1,940,000 | 8,954,000 | 3,999,000 | -3,628,000 | -1,493,000 | -134,000 | -7,825,000 | -26,429,000 | 5,196,000 | -290,000 | -3,015,000 | -6,948,000 | 1,266,000 | -1,511,000 | -6,294,000 | -18,472,000 | 12,816,000 | -16,749,000 | -10,122,000 | -5,110,000 |
accrued rebates, returns and discounts | -37,022,000 | -31,170,000 | 44,649,000 | 3,756,000 | 5,827,000 | 15,821,000 | 2,059,000 | 553,000 | -267,000 | -1,286,000 | -4,458,000 | -9,456,000 | 2,887,000 | 822,000 | -3,727,000 | -3,257,000 | 2,926,000 | 8,832,000 | -1,278,000 | -5,028,000 | -12,978,000 | 14,199,000 | -3,508,000 |
interest payable | -650,000 | -650,000 | -650,000 | 650,000 | -650,000 | 650,000 | -1,376,000 | -1,032,000 | -2,500,000 | 2,300,000 | 2,450,000 | -2,660,000 | 2,610,000 | -3,461,000 | 3,075,000 | ||||||||
net cash from operating activities | 8,563,000 | -29,968,000 | -4,767,000 | 19,091,000 | -12,538,000 | 11,548,000 | -35,000 | 7,387,000 | 7,508,000 | 5,707,000 | 2,579,000 | 18,601,000 | 22,717,000 | 26,697,000 | 10,045,000 | 14,430,000 | 27,426,000 | 4,131,000 | 4,654,000 | 964,000 | -4,226,000 | -5,982,000 | -14,431,000 |
capital expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -100,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1,000 | |
free cash flows | 8,563,000 | -29,968,000 | -4,767,000 | 19,091,000 | -12,538,000 | 11,548,000 | -35,000 | 7,387,000 | 7,508,000 | 5,607,000 | 2,579,000 | 18,601,000 | 22,717,000 | 26,697,000 | 10,045,000 | 14,430,000 | 27,426,000 | 4,131,000 | 4,654,000 | 964,000 | -5,982,000 | -14,432,000 | |
investing activities | |||||||||||||||||||||||
proceeds from maturities of short-term investments | 30,368,000 | 30,151,000 | 27,660,000 | 29,090,000 | 28,482,000 | 26,160,000 | |||||||||||||||||
purchases of short-term investments | -15,258,000 | -28,452,000 | -31,472,000 | -27,856,000 | -31,417,000 | -25,042,000 | -30,243,000 | ||||||||||||||||
net cash from investing activities | 15,110,000 | 1,699,000 | -3,812,000 | -6,940,000 | -2,935,000 | 1,118,000 | -6,709,000 | -239,000 | 4,144,000 | -703,000 | -105,000 | -25,784,000 | -371,000 | -16,114,000 | -404,000 | 0 | -1,000 | ||||||
financing activities | |||||||||||||||||||||||
payments related to the vesting and settlement of equity awards | -189,000 | -2,000 | -7,000 | -69,000 | -111,000 | -59,000 | -10,000 | -75,000 | -206,000 | -128,000 | 177,000 | ||||||||||||
net cash from financing activities | -189,000 | -2,000 | -7,000 | -69,000 | -111,000 | -59,000 | -10,000 | -75,000 | -206,000 | -8,915,000 | -10,000 | -16,326,000 | -18,950,000 | -798,000 | 2,888,000 | -7,441,000 | -2,443,000 | -7,522,000 | -356,000 | -7,569,000 | 44,473,000 | -7,969,000 | -10,234,000 |
net increase in cash and cash equivalents | 23,484,000 | -15,584,000 | 12,607,000 | -6,754,000 | -36,008,000 | 7,302,000 | -3,447,000 | 6,713,000 | 1,572,000 | 3,662,000 | 115,000 | 12,562,000 | -9,125,000 | 24,579,000 | -21,916,000 | 4,298,000 | -6,605,000 | 40,247,000 | |||||
cash and cash equivalents at beginning of year | 10,229,000 | 0 | 0 | 0 | 50,588,000 | 0 | 0 | 0 | 73,441,000 | 0 | 0 | 0 | 64,941,000 | 0 | 0 | 0 | 36,810,000 | 0 | 0 | 0 | 20,786,000 | 0 | 0 |
cash and cash equivalents at end of period | 33,713,000 | -8,586,000 | 12,082,000 | 35,004,000 | -6,754,000 | -36,008,000 | 80,743,000 | 6,713,000 | 1,572,000 | 68,603,000 | 12,562,000 | -9,125,000 | 61,389,000 | -21,916,000 | 4,298,000 | -6,605,000 | 61,033,000 | -13,951,000 | -24,666,000 | ||||
supplemental disclosure of cash flow information | |||||||||||||||||||||||
cash paid for interest | 1,300,000 | 0 | 1,300,000 | 0 | 1,300,000 | 0 | 1,300,000 | 0 | 1,300,000 | 0 | 1,300,000 | 0 | 2,351,000 | 0 | 3,004,000 | 4,908,000 | 0 | 5,498,000 | 887,000 | ||||
impairment of intangible assets | 0 | ||||||||||||||||||||||
loss on assertio therapeutics divestiture | 0 | 0 | |||||||||||||||||||||
payment of contingent consideration | -8,786,000 | 0 | -8,799,000 | -6,609,000 | 0 | -4,000,000 | -2,000,000 | -1,845,000 | -2,312,000 | 0 | |||||||||||||
changes in assets and liabilities, net of acquisition: | |||||||||||||||||||||||
assertio therapeutics divestiture | 0 | 0 | |||||||||||||||||||||
net decrease in cash and cash equivalents | -28,271,000 | -8,586,000 | -13,951,000 | ||||||||||||||||||||
cash and cash equivalents at end of year | |||||||||||||||||||||||
net cash (refunded) paid for income taxes | 4,000 | ||||||||||||||||||||||
net cash refunded (paid) for income taxes | 1,040,000 | ||||||||||||||||||||||
amortization of debt issuance costs and royalty rights | 113,000 | 111,000 | 108,000 | 107,000 | 105,000 | 102,000 | 101,000 | 147,000 | 176,000 | ||||||||||||||
loss on impairment of intangible assets | 40,808,000 | ||||||||||||||||||||||
debt-related expenses | 0 | 0 | 0 | 9,918,000 | |||||||||||||||||||
deferred income taxes | 29,009,000 | 48,577,000 | -18,000 | -1,367,000 | |||||||||||||||||||
proceeds from the sale of investments | |||||||||||||||||||||||
net cash acquired in spectrum merger | 0 | ||||||||||||||||||||||
purchases of property and equipment | -100,000 | 0 | 0 | -1,000 | |||||||||||||||||||
purchase of sympazan | -139,000 | 0 | -175,000 | -105,000 | |||||||||||||||||||
payments in connection with 2027 convertible notes | 0 | 0 | |||||||||||||||||||||
payment of direct transaction costs related to convertible debt inducement | 0 | 0 | 0 | -1,119,000 | |||||||||||||||||||
payment of royalty rights | -667,000 | 0 | -458,000 | -12,000 | |||||||||||||||||||
other financing activities | 458,000 | ||||||||||||||||||||||
net cash paid for income taxes | 206,000 | 4,000 | 1,373,000 | 11,000 | 469,000 | ||||||||||||||||||
provisions for inventory and other assets | 1,105,000 | 2,449,000 | 1,428,000 | 1,159,000 | 739,000 | 318,000 | 1,072,000 | ||||||||||||||||
proceeds from sale of short-term investments | |||||||||||||||||||||||
net income | -57,384,000 | -279,544,000 | 8,470,000 | -3,484,000 | 88,553,000 | 4,174,000 | 7,834,000 | 9,064,000 | -14,169,000 | 4,544,000 | -24,353,000 | -10,522,000 | |||||||||||
adjustments to reconcile net income to net cash from operating activities: | |||||||||||||||||||||||
proceeds from exercise of stock options | 0 | 0 | |||||||||||||||||||||
gain on extinguishment of debt | |||||||||||||||||||||||
purchase of otrexup | -10,138,000 | -371,000 | -16,114,000 | -404,000 | |||||||||||||||||||
proceeds from issuance of 2027 convertible notes | 4,084,000 | ||||||||||||||||||||||
payment in connection with 2024 senior notes | 0 | ||||||||||||||||||||||
payment of debt issuance costs | |||||||||||||||||||||||
proceeds from issuance of common stock | 0 | 0 | 0 | 0 | 0 | 44,861,000 | |||||||||||||||||
net cash paid (refunded) for income taxes | 607,000 | 1,129,000 | 2,266,000 | 29,000 | -8,360,000 | ||||||||||||||||||
proceeds from sale of investments | 0 | 0 | |||||||||||||||||||||
proceeds from the issuance of common stock | |||||||||||||||||||||||
payment in settlement of convertible debt inducement | -10,500,000 | ||||||||||||||||||||||
payment of taxes related to net share settlement of equity awards | -722,000 | ||||||||||||||||||||||
payments in connection with convertible notes | 0 | ||||||||||||||||||||||
shares withheld for payment of employee's withholding tax liability | -165,000 | -28,000 | -81,000 | -598,000 | -2,000 | -9,000 | -19,000 | -388,000 | 27,000 | ||||||||||||||
net cash received for refund of income taxes | |||||||||||||||||||||||
supplemental disclosure of non-cash investing activities | |||||||||||||||||||||||
deferred payments for acquisition of otrexup intangible assets | |||||||||||||||||||||||
recurring fair value measurement of assets and liabilities | 3,900,000 | 1,300,000 | 1,645,000 | 2,011,000 | 300,000 | 2,195,000 | -593,000 | -356,000 | 1,856,000 | ||||||||||||||
provision for inventory and other assets | 569,000 | 228,000 | 31,000 | -226,000 | |||||||||||||||||||
payments in connection with 2021 convertible notes | |||||||||||||||||||||||
net cash refunded for income taxes | 538,000 | ||||||||||||||||||||||
amortization of royalty rights | |||||||||||||||||||||||
payment in connection with series a-1 and a-2 debt | -4,750,000 | 0 | |||||||||||||||||||||
amortization of debt discount, debt issuance costs and royalty rights | 28,000 | 35,000 | 41,000 | 48,000 | 70,000 | 66,000 | |||||||||||||||||
impairment of goodwill | |||||||||||||||||||||||
loss on disposal of equipment and early termination of leases | |||||||||||||||||||||||
income tax provision | |||||||||||||||||||||||
gain on sale of gralise | 0 | 0 | |||||||||||||||||||||
loss on sale of nucynta | 0 | 0 | |||||||||||||||||||||
loss on extinguishment of convertible notes | |||||||||||||||||||||||
loss on prepayment of senior notes | 0 | 0 | |||||||||||||||||||||
income taxes | |||||||||||||||||||||||
cash acquired in zyla merger | 0 | 0 | |||||||||||||||||||||
proceeds from sale of nucynta | 0 | 0 | |||||||||||||||||||||
proceeds from sale of gralise | 0 | 0 | |||||||||||||||||||||
payments in connection with senior notes settlement | 0 | ||||||||||||||||||||||
payments on promissory note | 0 | 0 | |||||||||||||||||||||
payments on revolver | 0 | 0 | |||||||||||||||||||||
net cash refund of income taxes | |||||||||||||||||||||||
acquisition of otrexup intangible assets | |||||||||||||||||||||||
other | |||||||||||||||||||||||
payments in connection with convertible notes extinguishment | 0 | ||||||||||||||||||||||
benefit from inventory and other assets | 151,000 | ||||||||||||||||||||||
impairment of goodwill and intangible assets | |||||||||||||||||||||||
gain on extinguishment of convertible notes | 0 | ||||||||||||||||||||||
income taxes receivable | |||||||||||||||||||||||
purchases of marketable securities | |||||||||||||||||||||||
maturities of marketable securities | |||||||||||||||||||||||
sales of marketable securities | |||||||||||||||||||||||
payments in connection with debt extinguishment | |||||||||||||||||||||||
repayment of senior notes | |||||||||||||||||||||||
payment in connection with 13% senior secured notes | |||||||||||||||||||||||
payment of contingent consideration liability | |||||||||||||||||||||||
payment of royalty rights obligation | |||||||||||||||||||||||
payment of employees' tax liability related to common shares withheld | |||||||||||||||||||||||
convertible notes issuance costs | |||||||||||||||||||||||
fees for modification of senior notes | |||||||||||||||||||||||
net cash refund of (paid for) income taxes | |||||||||||||||||||||||
capital expenditures incurred but not yet paid | |||||||||||||||||||||||
loss on disposal of equipment | |||||||||||||||||||||||
deferred income tax benefit | |||||||||||||||||||||||
income tax receivable | |||||||||||||||||||||||
income taxes payable | |||||||||||||||||||||||
accretion of debt discount and debt issuance costs |